# Artivion Announces U.S. FDA Approval of the AMDS Hybrid Prosthesis
Canonical URL: https://biopharmsignal.com/news/AORT/artivion-announces-u-s-fda-approval-of-the-amds-hybrid-prosthesis-15da88f3
Ticker: AORT
Company: Artivion
Source: Artivion
Published: 2026-06-29 11:00 EST
Original Source URL: https://investors.artivion.com/news-releases/news-release-details/artivion-announces-us-fda-approval-amds-hybrid-prosthesis
## Summary

ATLANTA, June 29, 2026 /PRNewswire/ -- Artivion, Inc. (NYSE: AORT), a leading cardiac and vascular surgery company focused on aortic disease, today announced that the U.S. Food and Drug Administration (FDA) has approved the premarket approval application (PMA) for the AMDS Hybrid Prosthesis

## Article Body
ATLANTA, June 29, 2026 /PRNewswire/ -- Artivion, Inc. (NYSE: AORT), a leading cardiac and vascular surgery company focused on aortic disease, today announced that the U.S. Food and Drug Administration (FDA) has approved the premarket approval application (PMA) for the AMDS Hybrid Prosthesis
## Recent Company News
- 2026-06-29 11:00 EST — [Artivion Announces U.S. FDA Approval of the AMDS Hybrid Prosthesis](https://biopharmsignal.com/news/AORT/artivion-announces-u-s-fda-approval-of-the-amds-hybrid-prosthesis-15da88f3) — Source: Artivion
- 2026-06-25 13:46 EST — [Artivion to Participate in the 2026 Truist Securities MedTech Conference](https://biopharmsignal.com/news/AORT/artivion-to-participate-in-the-2026-truist-securities-medtech-conference) — Source: Artivion
- 2026-06-25 13:46 EST — [Artivion Completes Acquisition of Endospan Ltd.](https://biopharmsignal.com/news/AORT/artivion-completes-acquisition-of-endospan-ltd) — Source: Artivion
- 2026-06-25 13:46 EST — [Artivion Reports First Quarter 2026 Financial Results and Announces Exercise of Option to Acquire Endospan](https://biopharmsignal.com/news/AORT/artivion-reports-first-quarter-2026-financial-results-and-announces-exercise-of-option-to-acquire-endospan) — Source: Artivion
- 2026-06-25 13:46 EST — [Artivion Announces Release Date and Teleconference Call Details for Third Quarter 2025 Financial Results](https://biopharmsignal.com/news/AORT/artivion-announces-release-date-and-teleconference-call-details-for-third-quarter-2025-financial-results) — Source: Artivion
## Related News
- 2026-07-21 12:00 EST — MOR — [Novartis delivered sales growth in Q2 and further advanced the pipeline; Full-year guidance reaffirmed](https://biopharmsignal.com/news/MOR/novartis-delivered-sales-growth-in-q2-and-further-advanced-the-pipeline-full-yea-63a32b47)
- 2026-07-20 20:05 EST — RANI — [Rani Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)](https://biopharmsignal.com/news/RANI/rani-therapeutics-reports-inducement-grant-under-nasdaq-listing-rule-5635-c-4-ec56b3b0)
- 2026-07-20 14:53 EST — IPHA — [Innate Pharma announces Completion of Enrollment in Phase 1 Dose Escalation Study of IPH4502, a Novel Nectin-4 Exatecan Antibody-Drug Conjugate (ADC)](https://biopharmsignal.com/news/IPHA/innate-pharma-announces-completion-of-enrollment-in-phase-1-dose-escalation-stud-0778493f)
- 2026-07-20 13:05 EST — ACAD — [Acadia Pharmaceuticals Receives FDA Fast Track Designation for Remlifanserin in Alzheimer's Disease Psychosis](https://biopharmsignal.com/news/ACAD/acadia-pharmaceuticals-receives-fda-fast-track-designation-for-remlifanserin-in--f36b622c)
- 2026-07-20 13:00 EST — ENLV — [Enlivex Treasury Portfolio Update: NAV Per Ordinary Share $66.16; Total Treasury Holdings Valued at Approximately $1.1 Billion](https://biopharmsignal.com/news/ENLV/enlivex-treasury-portfolio-update-nav-per-ordinary-share-66-16-total-treasury-ho-9d036ef9)